Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of Skin Tumors in Tuberous Sclerosis
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), September 2008
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001975
  Purpose

Tuberous sclerosis is a rare, hereditary disease in which patients develop multiple tumors. Although not cancerous, the tumors can affect various organs, including the heart, lungs, kidneys, skin, and central nervous system, with serious medical consequences. The severity of disease varies greatly among patients, from barely detectable to fatal. This study will investigate what causes skin tumors to develop in patients with this disease.

Patients with tuberous sclerosis 18 years and older may enroll in this study. Participants will undergo a medical history and thorough skin examination by a dermatologist. Those with skin tumors will be asked to undergo biopsy (tissue removal) of up to eight lesions, under a local anesthetic, for research purposes. The biopsies will all be done the same day. The tissue samples will be used for: examination of genetic changes, measurement of certain proteins and other substances, and growing in culture to study the genetics of tuberous sclerosis.


Condition
Hereditary Neoplastic Syndrome
Tuberous Sclerosis

Genetics Home Reference related topics: familial encephalopathy with neuroserpin inclusion bodies tuberous sclerosis
MedlinePlus related topics: Cancer Skin Cancer Tuberous Sclerosis
U.S. FDA Resources
Study Type: Observational
Official Title: Cutaneous Tumorigenesis in Patients With Tuberous Sclerosis

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 130
Study Start Date: January 2000
Detailed Description:

Patients with tuberous sclerosis develop benign cutaneous tumors that are typically multiple in number and location. These tumors include facial angiofibromas, forehead plaques, shagreen patches, periungual fibromas, and gingival fibromas. The tumors are permanent, slow growing, and often disfiguring. The purpose of this study is to elucidate the molecular basis for these tumors. Specifically, we plan to identify the genetically altered cells in these hamartomatous lesions, and to quantify factors (e.g. cytokines) produced by these cells which induce the growth of these tumors. To accomplish this, we plan to obtain samples of these cutaneous tumors, to test tumor DNA for loss of heterozygosity, and to measure RNA and protein expression levels.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Patients will be those already diagnosed with TSC based on clinical criteria and/or genetic testing.

The clinical features of TSC considered of major significance are: facial angiofibromas or forehead plaque, nontraumatic periungual fibromas, three or more hypomelanotic macules, shagreen patch, multiple retinal nodular hamartomas, cortical tuber, subependymal nodule, subependymal giant cell astrocytoma, cardiac rhabdomyoma, lymphangioleiomyomatosis, and renal angiomyolipoma.

The minor features of TSC are: multiple randomly distributed pits in dental enamel, hamartomatous rectal polyps, bone cysts, cerebral white matter radial migration lines, gingival fibromas, nonrenal hamartoma, retinal achromic patch, "confetti" skin lesions, and multiple renal cysts.

EXCLUSION CRITERIA:

Inability to give informed consent.

Tendency to keloid formation.

Allergy to anesthetics.

Bleeding abnormality.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001975

Contacts
Contact: Mary Haughey, R.N. (301) 496-3632 mhaughey@nhlbi.nih.gov

Locations
United States, Maryland
United States Uniformed Health Service Recruiting
Bethesda, Maryland, United States, 20889
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 000051, 00-H-0051
Study First Received: January 20, 2000
Last Updated: October 9, 2008
ClinicalTrials.gov Identifier: NCT00001975  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Skin Biopsy
Familial Tumor Syndrome
Cell Growth
Loss of Heterozygosity
Cytokines
Tuberous Sclerosis

Study placed in the following topic categories:
Nervous System Malformations
Sclerosis
Skin Neoplasms
Neurodegenerative Diseases
Bourneville syndrome
Tuberous Sclerosis
Neoplastic Syndromes, Hereditary
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Tuberous sclerosis
Malformations of Cortical Development
Congenital Abnormalities
Neurocutaneous Syndromes

Additional relevant MeSH terms:
Neoplasms
Disease
Pathologic Processes
Syndrome
Nervous System Diseases
Hamartoma

ClinicalTrials.gov processed this record on January 15, 2009